Status:
WITHDRAWN
Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection
Lead Sponsor:
Queen Mary University of London
Collaborating Sponsors:
Imperial College London
Conditions:
Common Cold
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
A phase II randomised, placebo-controlled trial to identify the optimal regimen of vitamin D supplementation for rhinovirus protection, determined by host responses to a clinically induced rhinovirus ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 18-70 years
- Gives written informed consent
- Serum 25-hydroxyvitamin D concentration \<75 nmol/L
- Agrees not to take supplement containing vitamin D during participation
- Agrees not to commence smoking or vaping during participation
- Exclusion criteria:
- Current smoker or vaper
- Taken vitamin D supplement or other supplement containing vitamin D, in previous 3 months
- Sunny holiday abroadI, defined as any location 51 degrees North/South of the equator, for ≥1 week, in the previous 3 months
- Dependent(s) \<6 months old
- Positive serology for anti-RV16 antibodies
- Living with someone with severe airways disease
- Any of the following medical conditions:
- Diabetes mellitus
- Asthma
- Chronic Obstructive Pulmonary Disease
- Respiratory allergies
- Sarcoidosis
- Hyperparathyroidism
- Nephrolithiasis
- Active tuberculosis
- Liver failure
- Renal failure
- Lymphoma or other malignancy not in remission for ≥ 3 years
Exclusion
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04368520
Start Date
March 1 2020
End Date
May 1 2022
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Mary's Hospital
London, United Kingdom, W2 1NY